tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jain A et al. | Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267319 |
| Mueller AR et al. | Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267321 |
| Mohamed MA et al. | TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267336 |
| Shokouh-Amiri MH et al. | The importance of early prevention of renal dysfunction in liver transplant recipients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267345 |
| Markus BH et al. | Daclizumab induction therapy in combination with tacrolimus. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267354 |
| Langrehr JM et al. | IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267360 |
| Heffron TG et al. | Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267368 |
| Groetzner J et al. | Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? | 2001 Feb-Mar | Transplant. Proc. | pmid:11267373 |
| van den Berg AP et al. | Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267375 |
| Pirenne J et al. | Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267396 |
| Langrehr JM et al. | A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267404 |
| Heffron TG et al. | Daclizumab induction in liver transplant recipients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267408 |
| Rabkin JM et al. | Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267411 |
| Uber PA et al. | Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267428 |
| Banerjee R et al. | Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267435 |
| Mehra MR et al. | A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267438 |
| Mehra MR et al. | Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267442 |
| Treede H et al. | Incidence and spectrum of infections in lung transplanted patients: comparison of four different immunosuppressive protocols. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267444 |
| Jordan ML et al. | Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267456 |
| Lo A et al. | Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267465 |
| Burke GW et al. | Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267467 |
| Kahl A et al. | Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267473 |
| McCauley J et al. | Long-term lipid metabolism in combined kidney-pancreas transplant recipients under tacrolimus immunosuppression. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267475 |
| Lo A et al. | Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267477 |
| Owen ER et al. | Peripheral nerve regeneration in human hand transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267484 |
| Molmenti EP et al. | Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267487 |
| Spada M et al. | A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267495 |
| Lo A et al. | Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267516 |
| Reimer J et al. | Quality of life after kidney transplantation--the impact of tacrolimus. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267573 |
| Jain A et al. | Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. | 2001 | J Clin Pharmacol | pmid:11269567 |
| Bekersky I et al. | Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. | 2001 | J Clin Pharmacol | pmid:11269569 |
| Ericzon B et al. | Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. | 1994 | Transpl. Int. | pmid:11271178 |
| Undre N and Möller A | Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. | 1994 | Transpl. Int. | pmid:11271189 |
| Yano K et al. | Effects of intrahepatic arterial and intraportal administration of FK 506 on liver allograft survival in rats. | 1994 | Transpl. Int. | pmid:11271200 |
| Devlin J et al. | Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. | 1994 | Transpl. Int. | pmid:11271207 |
| Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. | 1994 | Transpl. Int. | pmid:11271216 | |
| Neuhaus P et al. | Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. | 1994 | Transpl. Int. | pmid:11271222 |
| Bismuth H et al. | Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. | 1994 | Transpl. Int. | pmid:11271231 |
| McMaster P | Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A. | 1994 | Transpl. Int. | pmid:11271239 |
| Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. | 1994 | Transpl. Int. | pmid:11271254 |
| D'Silva M et al. | The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation. | 1994 | Transpl. Int. | pmid:11271257 |
| Trocha K et al. | Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. | 1994 | Transpl. Int. | pmid:11271273 |
| Ishii T et al. | Immunodepressants ameliorate normothermic ischemia injury to the rat liver by down-regulating tumor necrosis factor, not by alleviation of lipid peroxidative injury. | 1994 | Transpl. Int. | pmid:11271294 |
| Platz KP et al. | Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. | 1994 | Transpl. Int. | pmid:11271297 |
| Metcalfe S et al. | FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes. | 1994 | Transpl. Int. | pmid:11271304 |
| Moutabarrik A et al. | Effect of immunosuppressive agents FK 506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytes. | 1994 | Transpl. Int. | pmid:11271305 |
| Winkler M et al. | Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. | 1994 | Transpl. Int. | pmid:11271312 |
| Devlin J et al. | FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group. | 1994 | Transpl. Int. | pmid:11271328 |
| Otto G et al. | Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. | 1994 | Transpl. Int. | pmid:11271338 |
| Wong P et al. | FK 506 rescue therapy for intractable liver allograft rejection. | 1994 | Transpl. Int. | pmid:11271339 |